Discussion
gastrointestinal symptoms

In the human intestine, We characterized the co-aggregation ability of In this study, we monitored gastric symptoms in patients to illustrate the positive modulating effect of FSCDJY67L3. It could significantly improve the gastrointestinal symptoms in We also evaluated the safety of After 30 days of intervention with The present study has a number of limitations that need to be acknowledged. We did not enroll infants and adolescents under 18 years of age in clinical trials. A study published in 